ArticleBMC cardiovascular disorders2026
Prognostic value of C-reactive protein-triglyceride-glucose index in hospitalised patients with acute decompensated heart failure.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe C-reactive protein-triglyceride-glucose index (CTI) is a composite marker integrating systemic inflammation and insulin resistance. Although CTI has been associated with cardiovascular risk in general and cardiometabolic populations, its prognostic significance in patients hospitalised with acute decompensated heart failure (ADHF) remains unclear.
methodsThis single-centre retrospective cohort study included 1,494 patients hospitalised with ADHF between January 2020 and June 2024. CTI was calculated as 0.412 × ln[CRP (mg/L)] + ln[TG (mg/dL) × FPG (mg/dL)/2], and patients were stratified into tertiles. The endpoints were all-cause mortality, cardiovascular (CV) death, and major adverse cardiac and cerebrovascular events (MACCEs). Associations between CTI and outcomes were assessed using multivariable Cox regression and restricted cubic spline analyses. Incremental prognostic performance beyond a comprehensive clinical model was evaluated using optimism-corrected Harrell's C-index, continuous net reclassification improvement (NRI), integrated discrimination improvement (IDI), time-dependent receiver operating characteristic curves, and decision curve analysis.
resultsDuring a median follow-up of 498 days, event rates increased progressively across CTI tertiles. In the fully adjusted model, each 1-standard deviation increase in CTI was independently associated with higher risks of all-cause mortality (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.29-1.80), CV death (HR 1.51, 95% CI 1.24-1.84), and MACCEs (HR 1.42, 95% CI 1.26-1.59). Patients in the highest CTI tertile had the greatest risk across all endpoints (all P for trend < 0.001). Restricted cubic spline analyses showed positive, approximately linear associations between CTI and all outcomes. Adding CTI to the clinical model yielded modest improvements in discrimination, with C-index increases from 0.665 to 0.672 for all-cause mortality, from 0.697 to 0.705 for CV death, and from 0.644 to 0.652 for MACCEs. Significant improvements in NRI and IDI were also observed for all outcomes.
conclusionsElevated CTI was independently associated with increased risks of all-cause mortality, CV death, and MACCEs in patients hospitalised with ADHF. Addition of CTI to a comprehensive clinical model provided modest but statistically significant incremental prognostic value beyond established clinical predictors and related metabolic or inflammatory markers evaluated in this study. CTI may serve as a simple adjunctive marker for metabolic-inflammatory risk profiling and refined risk stratification in ADHF, pending external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.